We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-4 of 4

IP provisions and ROI for state-funded stem cell-based products and technologies in California

  • Fenwick & West LLP
  • -
  • USA
  • -
  • May 31 2012

The California Institute of Regenerative Medicine (CIRM) reaches the end of its initial charter in 2017 and recently published its Transition Plan

Cardiac Pacemakers, Inc. v. St. Jude Medical, Inc.the Federal Circuit holds 35 U.S.C. 271(f) inapplicable to method claims

  • Fenwick & West LLP
  • -
  • USA
  • -
  • August 24 2009

On August 19, 2009, the Federal Circuit, sitting en banc, limited the reach of 35 U.S.C. 271(f), holding that the statute does not apply to method claims

Integra Lifesciences I, Ltd. v. Merck KGAA applying the Supreme Court's broad interpretation of the FDA exemption for patent infringement

  • Fenwick & West LLP
  • -
  • USA
  • -
  • July 30 2007

On July 27, the Federal Circuit in Integra LifeSciences v. Merck ruled on the Supreme Court's broad interpretation of the patent infringement exemption set forth in 35 U.S.C. 271(e)(1), for "uses reasonably related to the development and submission of information" to the Food and Drug Administration (FDA

Supreme Court in Medimmune opens the courthouse doors to licensees who challenge the scope or validity of licensed patents

  • Fenwick & West LLP
  • -
  • USA
  • -
  • April 2 2007

The Supreme Court has ruled that patent licensees do not need to breach their license agreements before seeking a declaratory judgment in federal court that the underlying patent is invalid, unenforceable, or not infringed